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Abstract
Background: It remains controversial as to whether HIV-1 subtypes influence disease progression. Singapore offers a unique
opportunity to address this issue due to the presence of co-circulating subtypes. We compared subtype CRF01_AE and non-
CRF01_AE infected patients, with regards to estimated annual rate of CD4+ T-cell loss and time from estimated data of
seroconversion (EDS) to antiretroviral therapy (ART).
Methods: We recruited ART-naive patients with known dates of seroconversion between October 2002 and December 2007
at the Singapore Communicable Disease Centre, the national reference treatment centre. Multilevel mixed-effects models
were used to analyse the rate of CD4+ T-cell decline. Time from EDS to ART was analyzed with the Kaplan-Meier survival
method and compared with Cox proportional hazards models.
Results: 54 patients with previously assigned HIV-1 subtypes (24 CRF01_AE, 17 B, 8 B’, 1 CRF33_01B, 3 CRF34_01B and 1 G)
were observed for 89 patient-years. Subtype CRF01_AE and non-CRF01_AE infected patients did not differ in age, gender,
risk factor, rate of symptomatic seroconversion, baseline CD4+ T-cell count, log10 viral load or haemoglobin concentration.
The estimated annual rate of CD4+ T-cell loss was 58 cells/mm
3/year (95% CI: 7 to 109; P=0.027) greater in subtype
CRF01_AE infected patients compared to non-CRF01_AE patients, after adjusting for age, baseline CD4+ T-cell count and
baseline log10 viral load. The median time from EDS to ART was 1.8 years faster comparing CRF01_AE to non-CRF01_AE
infected patient with a 2.5 times (95% CI: 1.2-5.0; P=0.013) higher hazard for ART initiation, after controlling for age,
baseline CD4+ T-cell count and baseline log10 viral load.
Conclusions: Infecting subtype significantly impacted the rate of CD4+ T-cell loss and time to treatment in this cohort.
Studies to understand the biological basis for this difference could further our understanding of HIV pathogenesis.
Citation: Ng OT, Lin L, Laeyendecker O, Quinn TC, Sun YJ, et al. (2011) Increased Rate of CD4+ T-Cell Decline and Faster Time to Antiretroviral Therapy in HIV-1
Subtype CRF01_AE Infected Seroconverters in Singapore. PLoS ONE 6(1): e15738. doi:10.1371/journal.pone.0015738
Editor: Nitika Pant Pai, McGill University, Canada
Received October 15, 2010; Accepted November 26, 2010; Published January 27, 2011
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: A Singapore National Medical Research Training Fellowship grant (MH 95:03/8-169) provided salary support for OT Ng. Additional support was
provided by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: oong@jhsph.edu
Introduction
The global HIV-1 pandemic is characterized by extensive
genetic diversity [1]. Uncertainty exists as to whether different
subtypes manifest different pathogenicity, and by implication
different host-pathogen interactions [2]. Genotypic differences in
viral pathogenicity have implications in determining viral
genotypic motifs important to disease progression, vaccine
development and disease transmission [3]. Clinical guidelines
may have to be subtype-specific if significant differences exist [4,5].
Currently, the overwhelming majority of data on HIV-1 is based
on subtype B, the predominant subtype in developed countries.
However, subtype B accounts for only 10% of infections
worldwide [2].
Two recent studies from northern Thailand with cohorts of
subtype CRF01_AE infected patients reported a 3-year shorter
median survival compared to age-matched individuals for the
Western CASCADE cohort, where subtype B predominates
[6,7,8]. This reduced survival could have been due to viral, host
or environmental differences between the Thai and Western
cohorts.
In Singapore, subtypes CRF01_AE and B exist in near equal
proportions [9]. Patients treated at our centre have regular CD4+ T-
cell count monitoring. This unique setting enabled us to study
subtype differences in disease progression and corresponding clinical
implications. The primary objective of our study was to determine the
difference between subtype CRF01_AE and other circulating
subtypes in the pre-ART annual rate of CD4 decline in subjects
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15738with known dates of seroconversion. Furthermore, we examined the
time from infection to ART initiation by infecting subtype.
Methods
Study population
Details of the study participants and laboratory protocols have
been previously published [9]. In brief, patients identified as
seroconverters within a prior 2-year window by treating physicians
at the Communicable Disease Centre from October 2002 to
December 2007 were recruited. Inclusion criteria were either: (1) a
previous negative HIV antibody test within 24 months of study
entry followed by a positive test; (2) an indeterminate Western blot
within 24 months of study entry followed by a positive test; (3)
clinical syndrome consistent with seroconversion illness following
recent risk factor for HIV-1 exposure with prior negative HIV
antibody test within 24 months of study entry. After obtaining
written consent, blood drawn for HIV-1 genotyping was
centrifuged to obtain plasma samples stored at 280uC. Follow-
up was per routine clinical care, where patients were seen at 3 to 6
monthly intervals with standard of care interventions provided
following recognized guidelines [10,11].
Clinical data was obtained from chart review. Only patients
with 2 or more CD4+ T-cell counts measurements from at least 3
months following EDS were included in the current study. The 3-
month interval was chosen to exclude results from the period of
wide variability in CD4+ T-cell counts during recent seroconver-
sion. Patients were followed until mid-May 2010 via chart review
or censored either at ART initiation or loss to follow up (defined as
more than 1 year without a clinic visit).
Informed written consent was obtained from all participants.
The National Healthcare Group ethics committee approved this
study and its guidelines were followed in the conduct of this study.
Laboratory analysis
As published, HIV-1 pol gene sequences were previously
determined using the Celera Diagnostics ViroSeq HIV-1 Geno-
typing System (version 2.0) (Celera Diagnostics, USA). Phyloge-
netic analysis for sub-typing against reference sequences from the
Los Alamos HIV Sequence Database has been published [9].
CD4+ T-cell counts were analysed on the Becton Dickinson
FACSCalibur analyser (Becton Dickinson International, Belgium).
Plasma viral load was determined by the AMPLICOR HIV-1
MONITOR version 1.5 (Roche Molecular Systems, USA) before
May 2007. After May 2007, the Abbott RealTime HIV-1 assay
(Abbott Molecular Inc, USA) was used.
Statistical analysis
The estimated date of seroconversion (EDS) was defined in
order of priority as: (1) date of onset of clinical seroconversion
syndrome, (2) date of indeterminate Western blot or (3) midpoint
between date of last negative and first positive HIV-1 serology.
Baseline CD4+ T-cell count was defined as the first result available
at least 3 months from EDS. Viral loads in copies/ml were log10-
transformed and those above the detectable limit were given the
value equivalent to 750,000 copies/ml, the upper limit of the
Roche assay. No result exceeded the detectable limit of the Abbott
assay of 10 million copies/ml. The mode of transmission was
divided into 5 categories (heterosexual, homosexual, bisexual,
injection drug use and unknown). HIV-1 subtypes were dichot-
omised into subtype CRF01_AE and non-CRF01_AE. Baseline
characteristics were compared between the subtype groups by
Student’s t-test and Wilcoxon Rank-Sum test for continuous
variables and Fisher’s exact test for categorical variables.
Multilevel linear mixed-effects models with unstructured
covariance were used to estimate the annual rate of CD4+ T-
cell decline [12]. The final model adjusted for age, baseline CD4+
T-cell count and baseline log10-transformed viral load. Presence
of symptomatic seroconversion, mode of transmission and baseline
haemoglobin level were dropped from the final model, as they did
not improve model fit. As previous investigators used square-root
transformation of CD4+ T-cell count to stabilize variance, the
final model was repeated with transformation to ensure inferences
were unaltered [4,13].
The Kaplan-Meier survival method was used to examine
progression from EDS to ART initiation. Cox proportional
hazards models were used to estimate crude and adjusted hazard
ratios for this endpoint. All analyses were performed using Stata 11
(Stata Corporation, USA), and all tests were conducted as 5%
significance level.
Results
Population characteristics
54 patients met the inclusion criteria. Subtype distribution was
as follows: 24 CRF01_AE, 17 B, 8 B’, 1 CRF33_01B, 3
CRF34_01B and 1 G. The median age was 30.6 years (range:
17.2 to 57.9 years). The majority of patients were men (98%) and
of Chinese ethnicity (96%). Risk factor for HIV-1 acquisition was
homosexual exposure in 27 patients (50%), heterosexual in 13
patients (24%), bisexual in 7 patients (13%), intravenous drug use
(IDU) in 1 (2%) patient and 6 (11%) patients with no self-reported
risk. 50% of the patients had a history of symptoms consistent with
seroconversion illness.
The mean baseline CD4+ T-cell count was 408 cells/mm3 (s.
d.: 197 cells/mm3) with a median time from EDS to baseline
count of 6.4 months (IQR: 4.8 to 7.9 months). Mean baseline
log10-transformed viral load was 4.8 (s. d.: 0.76) obtained at
median time from EDS of 5.8 months (IQR: 3.3 to 10 months).
The total observation time was 89 patient years. The median
follow-up time from baseline CD4+ T-cell count to last recorded
pre-ART CD4+T-cell count was 1.8 years (IQR: 1 to 2.3 years). 6
patients (2 CRF01_AE and 4 non-CRF01_AE) defaulted follow up
after a median duration of 1.1 years (IQR: 0.7 to 2.1 years). There
were no statistically significant demographic or baseline laboratory
test differences between the two subtype groups (Table 1).
Rate of CD4+ T-cell Decline
The overall average rate of CD4+ T-cell decline without regard
to subtype was 56 cells/mm
3 per year (95%CI: 30 to 82 cells/mm
3),
controlling for age, baseline CD4+ T-cell count and log10 viral load.
In the multilevel model including subtype, CRF01_AE infected
patients had an average decline of 90 cells/mm3 per year (95%CI:
50 to 131 cells/mm3) compared to 32 cells/mm
3 per year for non-
CRF01_AE infected patients (95%CI: 1 to 64 cells/mm3), after
controlling for age, baseline CD4+ T-cell count and log10 viral load.
The difference in average yearly decline between the two subtype
categories was statistically significant (P=0.027) (Table 2). Square-
root transformation of CD4+ T-cell count did not change the study
inference; the rate of decline for subtype CRF01_AE infected
patients compared to other subtypes remained significantly higher
after adjusting for age, baseline CD4+ T-cell count and log10 viral
load (-1.83/year; 95%CI: 0.27 to 3.40; P=0.022).
Time from EDS to ART initiation
A greater proportion of CRF01_AE infected patients initiated
ART (79% compared to 47%; P=0.024) with similar CD4+ T-
cell counts at ART initiation in the two groups (Table 1). The
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CRF01_AE infected patients compared to 3.8 years (95% CI
lower limit: 2.4) for non-CRF01_AE infected patients (Figure 1).
Using Cox proportional hazards, the unadjusted hazard ratios
comparing CRF01_AE to non-CRF01_AE infected patients was
2.5 (95%CI: 1.2 to 5.0; P=0.013). After adjusting for age, baseline
CD4+ T-cell count and log10 viral load, the HR was unchanged at
2.5 (95%CI: 1.2 to 5.1; P=0.015).
Discussion
In this cohort of seroconverters from Singapore, subtype status
was strongly correlated with rate of CD4+ T-cell loss. Subtype
CRF01_AE infected patients had a mean 58 cell/mm
3/year greater
adjusted loss of CD4+ T-cells compared to other infecting subtypes
(mainly B) in our study. The resultant clinical outcomes were
markedly different in that the median time to treatment initiation
was 1.8 years faster in subtype CRF01_AE infected patients.
Differences in subtype progression have been documented in
Africa [14,15]. A recent study examining the differences in CD4+
T-cell loss between subtypes in Uganda reported a 73.7 cell/mm
3
greater yearly loss in subtype D compared to subtype A infected
patients [16]. In Southeast Asia, 2 studies from subtype
CRF01_AE infected patients in Thailand reported shorter median
survival times of 3 years compared to age-matched patients from
Western cohorts, where subtype B predominates [6,7]. This
comparison was potentially confounded by inter-geographic
differences in host genetics or access to care [4]. Our study was
conducted in an overwhelmingly male Chinese population with
universal access to healthcare [17]. There was no detectable
baseline host difference between the co-circulating subtypes that
would explain the phenotypic differences. Our results provide
supportive evidence that infection with a CRF01_AE subtype
contributed to the decreased survival reported from Thailand.
A study of injecting heroin users in Bangkok reported higher
viral loads in subtype CRF01_AE compared to subtype B infected
Table 2. Independent predictors of rate of CD4 decline
a.
Difference in annual rate of
CD4+ T-cell decline (cells/mm3/year) 95% Confidence Interval P-value
Subtype (CRF01_AE vs non-CRF01_AE) –58 –7 to –109 0.027
Baseline CD4+ T-cell count (per 100 cells/mm3 increase) –21 –8 to –34 0.001
Baseline log10 viral load (per 1 log increase) –32 –64 to 1 0.060
aCo-variates in the model were subtype, baseline CD4+ T-cell count, baseline log10 viral load and age. Baseline log10 viral load was borderline statistically significant.
doi:10.1371/journal.pone.0015738.t002
Table 1. Characteristics of patients by HIV-1 subtype
a.
Subtype CRF01_ _AE (n=24) Non-CRF01_ _AE (n=30) P-value
Age in years (median,IQR) 34.7 (27.4–42.3) 30.4 (27.5–37.0) 0.338
Male (number, column %) 23 (95.8) 30 (100) 0.444
Mode of transmission (number; column %)
Heterosexual 7 (29) 6 (20) 0.813
Homosexual 11 (46) 16 (53)
Bisexual 3 (13) 4 (13)
IDU 1 (4) 0 (0)
Unknown 3 (13) 4 (13)
Symptomatic seroconversion (number, column %) 13 (54) 14 (47) 0.392
Baseline CD4+ T-cell count (cells/mm3) (mean, sd) 406 (209) 411 (191) 0.928
Baseline log10 transformed viral load (median, IQR) 4.97 (4.39–5.70) 4.71 (4.31–5.23) 0.172
Baseline haemoglobin (g/dL) (mean, sd) 14.0 (1.5) 14.4 (1.2) 0.318
Estimated date of seroconversion (EDS) (median, IQR) Jan 2007 (Mar 2006 to April 2007) December 2006 (October
2005 to Mar 2007)
0.741
Months from EDS to baseline CD4 (median, IQR) 6.3 (3.5–6.8) 6.5 (5.1–8.7) 0.304
Months from EDS to baseline viral load (median, IQR) 4.5 (3.1–10.3) 6.1 (3.5–12.2) 0.309
Median number of CD4 counts per patient (median, IQR) 6 (4–7) 6 (4–7) 0.604
Number initiated treatment (number, column %) 19 (79) 14 (47) 0.024
CD4+ T-cell count at treatment initiation (number, column %)
,250 cells/mm
3 13 (68) 7 (50) 0.273
250–350 cells/mm
3 5 (26) 7 (50)
.350 cells/mm
3 1 (5) 0 (0)
aStatistical tests as detailed in methods section.
doi:10.1371/journal.pone.0015738.t001
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difference was documented in the rate of decline of CD4+ T-cell
counts up to 2 years following seroconversion between CRF01_AE
and B infected individuals [18]. Our study population compared
to the Bangkok cohort had different risk profiles and potentially
different access to medical care. In addition, both our study and
the Bangkok cohort did not have data on host genetics, an
interesting area of future research.
A recent study from Canada demonstrated longer time to
treatment initiation among non-subtype B (mainly C, CRF02_AG
and A) infected patients compared to subtype B [4]. In our study,
CRF01_AE compared to B infected patients had a shorter time to
ART initiation. If confirmed in larger cohorts, subtype status could
contribute to clinical prognostication.
In conclusion, we document a marked difference in CD4+ T-
cell decline and time to treatment comparing CRF01_AE and
non-CRF01_AE HIV-1 infection in Singapore. Larger studies to
confirm this result are planned. If confirmed, studies to understand
the biologic basis for these differences could bear fruit to further
our understanding of HIV-1 pathogenesis.
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